Genentech's Fenebrutinib Is First Bruton's Tyrosine Kinase Inhibitor to Receive U.S. Food & Drug Administration Filing Acceptance in Both Relapsing, Primary Progressive Multiple Sclerosis
September 30, 2026
September 30, 2026
SOUTH SAN FRANCISCO, California, Sept. 30 (TNSrep) -- Genentech, a member of the Roche Group, issued the following news release:
* * *
Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
* Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability . . .
* * *
Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
* Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability . . .